Guggenheim initiated coverage on UroGen Pharma with a new price target
$URGN
Biotechnology: Pharmaceutical Preparations
Health Care
Guggenheim initiated coverage of UroGen Pharma with a rating of Buy and set a new price target of $40.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/16/2025 | $50.00 | Neutral → Buy | H.C. Wainwright |
| 5/22/2025 | Buy → Neutral | H.C. Wainwright | |
| 4/16/2025 | $23.00 | Sector Outperform | Scotiabank |
| 2/19/2025 | $31.00 | Buy | Ladenburg Thalmann |
| 8/22/2024 | $40.00 | Buy | Guggenheim |
| 2/8/2023 | $35.00 → $10.00 | Buy → Hold | Jefferies |
| 4/27/2022 | $20.00 | Buy | Berenberg |
| 1/18/2022 | $50.00 → $34.00 | Buy | HC Wainwright & Co. |